ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Nuclear Translocation of PFKFB3 Promotes Disuse-Induced Muscle Atrophy via Scaffolding Nedd4-Mediated JunB Ubiquitination.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Disuse-induced muscle atrophy is characterized by coordinated metabolic remodeling and enhanced protein degradation, yet the molecular link between these processes remains unclear. Here, we identify 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) as a critical regulator of this condition. Using a unilateral hindlimb immobilization mouse model, metabolomics, and functional assays in vivo and in vitro, we demonstrate that PFKFB3 is markedly upregulated during muscle atrophy and promotes myofiber wasting. Mechanistically, PFKFB3 predominantly localizes to the nucleus and functions independently of its canonical glycolytic activity. It acts as a scaffold protein to facilitate the interaction between the E3 ubiquitin ligase Nedd4 and the transcription factor JunB, thereby enhancing JunB ubiquitination and proteasomal degradation. Loss of JunB, a known anti-atrophy factor, contributes to atrophic progression. In turn, JunB transcriptionally represses PFKFB3, forming a regulatory feedback loop. Pharmacological and genetic inhibition of the PFKFB3-Nedd4-JunB axis significantly attenuates muscle atrophy in vivo. Collectively, these findings reveal a noncanonical nuclear function of PFKFB3 in coordinating protein stability during muscle atrophy and highlight this signaling axis as a potential therapeutic target for disuse-induced muscle wasting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.